Journal of Medicinal Chemistry · 1999 · 21 citations · 17 references
Life SciencesMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryEnzymologyAntibody-drug ConjugatesEnzyme DiscoveryEnzyme InhibitionEnzyme TargetsProteolytic EnzymesTherapeutic EnzymesAntibody-directed Enzyme Prodrug TherapyAntibody-directed ProdrugsCombination Prodrug TherapyEnzyme Inhibitor SynthesisEnzyme-targeted ProdrugsL-amino Acid ProdrugsTherapeutic Enzyme Discovery
The design and synthesis of potent thiocarbamate inhibitors for carboxypeptidase G2 are described. The best thiocarbamate inhibitor N-(p-methoxybenzenethiocarbonyl)amino-L-glutamic acid 6d, chosen for preliminary investigations of in vitro antibody-directed enzyme prodrug therapy (ADEPT), abrogated the cytotoxicity of a combination of A5B7-carboxypeptidase G2 conjugate and prodrug PGP (N-p-{N,N-bis (2-chloroethyl)amino}phenoxycarbonyl-L-glutamate) toward LS174T cells. This is the first report of a small-molecule enzyme inhibitor proposed for use in conjunction with the ADEPT approach.
17
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Antibody directed enzymes revive anti-cancer prodrugs concept
K D Bagshawe · British Journal of Cancer · 1987 · 278 citations · Full text
Roger F. Sherwood, Roger G. Melton, Shakir M. Alwan et al. · European Journal of Biochemistry · 1985 · 210 citations · Full text